# Determination of the Minimal Clinically Important Difference After Treatment With Pantoprazole in Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-340)

> **NCT00246909** · PHASE4 · COMPLETED · sponsor: **Takeda** · enrollment: 600 (—)

## Conditions studied

- Gastroesophageal Reflux

## Interventions

- **DRUG:** Pantoprazole

## Key facts

- **NCT ID:** NCT00246909
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2006-11
- **Final completion:** 2006-11
- **Target enrollment:** 600 (—)
- **Last updated:** 2012-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00246909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00246909, "Determination of the Minimal Clinically Important Difference After Treatment With Pantoprazole in Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-340)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00246909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*